Previous Article | Next Article ![]()
Molecular and Cellular Biology, October 2004, p. 8366-8373, Vol. 24, No. 19
0270-7306/04/$08.00+0 DOI: 10.1128/MCB.24.19.8366-8373.2004
Copyright © 2004, American Society for Microbiology. All Rights Reserved.
Sam and Ann Barshop Center for Longevity and Aging Studies,1 Department of Cellular and Structural Biology,2 Department of Microbiology and Immunology, The University of Texas Health Science Center at San Antonio, San Antonio,3 Departments of Pathology,4 Molecular and Cellular Biology,5 Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas6
Received 16 April 2004/ Returned for modification 28 May 2004/ Accepted 13 July 2004
|
|
|---|
|
|
|---|
We obtained a novel cDNA PAM14 (for protein associated with MRG, 14 kDa) that interacts with all three MORF4/MRG proteins as well as Rb, an important tumor suppressor protein (13). Our laboratory has found that MRG15 and MRGX can activate the B-myb promoter in HeLa cells, most likely by disruption of the E2F/Rb/histone deacetylase complex known to interact with the E2F site in this promoter (12, 13, 29). Since MORF4 is a truncated version of MRG15 and MRGX, our working hypothesis is that MORF4 acts to replace and disrupt or inactivate complexes containing these proteins, with a resulting modulation of gene expression and loss of cell proliferation in a subset of immortal human cells. MORF4 is so similar to MRG15 (2) that it has been difficult to develop tools to study this gene and protein directly. To provide insights into the mechanism(s) of action of the MORF4/MRG proteins, we inactivated the Pam14 gene, since PAM14 interacts with all three and is ubiquitously expressed. The results demonstrated that Pam14 null (Pam14/) mice were viable and appeared to have normal fertility. Analysis of the proliferative response of mouse embryonic fibroblasts (MEFs) and splenic T lymphocytes to mitogen stimulation demonstrated that Pam14/ cells were equivalent to cells from wild-type and heterozygous animals in growth response and expression of genes related to cell cycle initiation and progression. These results suggest that PAM14 is not required for either development or the cell proliferation response and that its function is likely compensated for by another protein(s).
|
|
|---|
Plasmids. A hemagglutinin (HA)-tagged mouse PAM14 (mPAM14)-encoding fragment was amplified with Pfu DNA polymerase, using the genomic clone as a template. PCR was achieved with the following primers: mPAM14-5', 5'-CGC GGA TCC GCC ACC ATG CGG CCC CTG GAC GCG GT-3' and mPAM14-3', 5'-CCG GAA TTC TCA AGC GTA ATC TGG AAC ATC GTA TGG GTA CGA AGA CTC GCT CTT CTC TAT CC-3'. Construction of a V5-tagged mouse MRG15 (mMRG15) plasmid has been reported previously (31).
Immunoprecipitation and Western blot analysis. HeLa cells transfected with PAM14 and/or MRG15 expression plasmids were washed with phosphate-buffered saline and scraped into 1 ml of lysis buffer (20 mM Tris-HCl [pH 7.5], 150 mM NaCl, 10% glycerol, 1% NP-40, and protease inhibitor cocktail set I [Calbiochem, San Diego, Calif.]) per 100-mm dish. The lysed cells were put into 1.5-ml tubes and kept for 30 min on ice. Following centrifugation at 17,000 x g for 15 min at 4°C, the supernatants were collected and protein concentrations were determined with the Bio-Rad protein assay, using bovine serum albumin as a standard. For immunoprecipitation, 500 µg of protein was precleared for 1 h by addition of Bio-Mag beads (QIAGEN). The antibody was added to the precleared lysates and kept at 4°C for 1 h. Bio-Mag beads were added to each tube and kept at 4°C overnight. Beads were washed four times with 0.5 ml of lysis buffer, and 1x loading buffer (25 mM Tris-HCl [pH 6.5], 5% glycerol, 1% SDS, 1% 2-mercaptoethanol, and 0.05% bromphenol blue) was then added. Samples were boiled for 3 min and run on SDS-polyacrylamide gel electrophoresis (SDS-PAGE) gels. The separated proteins were blotted on nitrocellulose membranes (Bio-Rad), which were probed with antibody and subsequently with horseradish peroxidase-conjugated second antibody. To visualize the proteins, a standard enhanced chemiluminescence reaction was employed (ECL; Amersham Biosciences).
Nuclear extracts were prepared from two spleens of C57BL/6J females as described previously (27) and diluted 1:2 in 25 mM Tris-HCl (pH 7.5). The nuclear protein (300 µg) was incubated with 4 µg of either rabbit anti-Rb (M-153; Santa Cruz Biotechnology sc-7905), rabbit anti-MRG15 (our laboratory), or rabbit anti-HA (Y-11; Santa Cruz Biotechnology sc-805) antibody overnight, and protein A-agarose was then added for 1 h. After four washes with buffer (25 mM Tris-HCl [pH 7.5], 210 mM NaCl, 0.75 mM MgCl2, 0.25 mM EDTA, and 12.5% sucrose), immunoprecipitates were run on SDS-PAGE gels followed by Western blot analysis, as described above.
Construction of Pam14 targeting vector. A 5' homologous 3.2-kb BamHI-NotI fragment was blunted with T4 DNA polymerase (Gibco-BRL) and ligated to HindIII-EcoRI adaptors (Stratagene). After purifying the fragment, it was subcloned into a PgkHPRT selectable marker cassette. A 3' homologous 4.1-kb HincII-XhoI fragment was blunted and ligated to XbaI-XmnI adaptors (New England BioLabs, Beverly, Mass.), and this fragment was then subcloned into the PgkHPRT cassette vector containing the 5' homology arm region. Finally, the MC1tk expression cassette, for negative selection, was subcloned next to the 3' homologous region by using the NotI site.
Generation of mice harboring the Pam14 mutation.
Twenty-five micrograms of ClaI-linearized targeting vector was electroporated into 107 129/SvEv-derived AB2.1 embryonic stem (ES) cells. ES cells were then selected in medium containing hypoxanthine-aminopterin-thymidine and 1-(2'-deoxy-2'-fluoro-ß-D-arabinofuranosyl)-5'-iodouracil (FIAU). For genomic Southern blot analysis, EcoRV- or BamHI-digested DNA was transferred to GeneScreen Plus nylon membranes (NEN Life Science Products, Boston, Mass.) and probed with an external
500-bp SphI-BamHI fragment as 5' probe or an external
650-bp NcoI-NcoI fragment as 3' probe, respectively. Mutant ES clones were injected into C57BL/6J blastocysts, and chimeric males were mated with C57BL/6J females. Germ line transmission was obtained from chimeras derived from two independent clones (16).
Northern blot analysis. RNA was isolated from tissues or MEFs by using the TRIzol reagent (Invitrogen). Frozen tissue samples were homogenized with a 1.5-ml pellet pestile, 1 ml of TRIzol was added to the tissue sample, and the suspension was passed through a 21-gauge needle to shear the DNA. RNA was extracted according to the manufacturer's instructions RNA was resolved on a 1% agarose gel and then transferred to a Hybond-N+ nylon membrane. Blots were hybridized in NorthernMax hybridization buffer (Ambion, Austin, Tex.) at 42°C overnight with a 320-bp SacI-SmaI probe from the mouse Pam14 genomic clone. This fragment contains a 44-bp 5' noncoding region and most of the coding region. The fragment of Mrg15 to be used as probe was amplified by PCR using MRG15-5'end primer, 5'-GGC AAA TCG CGC CCA GGA TGT AGA-3', and Exon 3R primer, 5'-CCA GCC ACT GTA ATG GAT GAA GTA-3'. This fragment contained 131 bp of the 5' untranslated region and 147 bp of the coding region of Mrg15 and did not cross-hybridize with mouse MrgX (31). Plasmids which contained mouse cyclin E1 (Ccne1), cyclin D1 (Ccnd1), Mybl2, and Myc fragments for probes were kindly provided by Nicholas J. Dyson. The blot was washed with 2x SSC-0.1% SDS at 65°C twice for 10 min and then washed with 0.2x SSC-0.1% SDS at 65°C twice for 15 min.
Antibody preparation. A bacterially expressed intein-human PAM14 (hPAM14) fusion protein (expression plasmid kindly provided by F. Quiocho) or glutathione S-transferase-human MRG15 was purified using chitin beads (New England BioLabs) or glutathione-Sepharose 4B (Amersham Biosciences), respectively, according to the instruction manuals. Rabbits were immunized with the purified proteins, and a polyclonal antibody was generated by Cocalico Inc. The antibodies against PAM14 and MRG15 were affinity purified using an antigen-binding Sepharose column (HiTrap; Amersham Biosciences).
Generation of MEFs. MEFs were derived from 13.5-day-old wild-type, Pam14+/, and Pam14/ embryos. After removal of the head and gastrointestinal tract, each embryo was washed with phosphate-buffered saline and minced, and the tissue was placed in a 15-ml conical tube. After centrifugation, 1 ml of trypsin solution (0.25% trypsin-0.005% EDTA) was added to the pelleted tissue and the tissue was digested on ice overnight. Trypsin was inactivated by the addition of Hank's minimum essential medium (Invitrogen) containing 10% fetal bovine serum (FBS), 2 mM glutamine, 0.1 mM nonessential amino acids, 28 mM HEPES, 100 U of penicillin G per ml, and 100 µg of streptomycin per ml. After pipetting several times, the single-cell suspension was plated into one T75 tissue culture flask and incubated at 37°C for 2 to 3 days until the cells were confluent. We designated this culture as PD0. Using a 3T3 culture regimen (28), 3 x 105 cells were replated every 3 days onto 60-mm tissue culture dishes using Eagle's minimum essential medium (Invitrogen) containing 10% FBS, 2 mM glutamine, and 0.1 mM nonessential amino acids in a 5% CO2 humidified chamber. Immortalized cells were occasionally obtained during continuous culture.
T-cell response assay. For analysis of T-cell response, single-cell suspensions were prepared from spleens of wild-type, heterozygous, and null mice at 4 weeks of age. Splenic tissue was homogenized between frosted glass slides in T-cell medium (RPMI 1640 containing 10% FBS, 0.1 mM nonessential amino acids, 100 U of penicillin per ml, and 100 µg of streptomycin per ml). A total of 2 x 104 splenocytes were plated into each well of a 24-well plate and stimulated with various concentrations of concanavalin A (ConA) or 10 ng of phorbol myristate acetate (PMA) per ml plus 100 ng of ionomycin per ml for 48 h. The culture supernatants were centrifuged at 2,700 x g for 10 min, and the supernatants were stored at 80°C until assayed. Interleukin-2 (IL-2) was measured using an IL-2 enzyme-linked immunosorbent assay (ELISA) kit (BD Pharmingen).
|
|
|---|
![]() View larger version (14K): [in a new window] |
FIG. 1. Structure of mouse Pam14 genomic DNA and protein sequence similarity of mouse and human PAM14. (A) Schematic diagram of the mouse Pam14 gene. (B) Alignment of amino acid sequences of mPAM14 and hPAM14. Identical amino acids are marked with black boxes, and similar amino acids are shown with gray boxes.
|
![]() View larger version (56K): [in a new window] |
FIG. 2. PAM14 is expressed ubiquitously in mouse tissues. A dot blot of poly(A)+ RNA from multiple mouse tissues (mouse RNA master blot; no. 7771-1; Clontech) was probed with the mouse Pam14 coding region.
|
![]() View larger version (42K): [in a new window] |
FIG. 3. mPAM14 interacts with MRG15 and Rb. (A) HeLa cells were cotransfected with expression vectors, and lysates were subjected to immunoprecipitation (IP) and Western blot (WB) analysis with antibodies as indicated. (B) Nuclear extracts from splenocytes of C57BL/6J females were immunoprecipitated using anti-Rb, anti-MRG15, or anti-HA (negative control) antibodies, and detection of the presence of Rb, PAM14, and MRG15 proteins in the immunoprecipitates by Western blot analysis was done using anti-Rb, anti-PAM14, and anti-MRG15 antibodies.
|
Targeted disruption of the Pam14 gene. To disrupt the Pam14 gene, the entire coding region was replaced with a PgkHPRT cassette (Fig. 4A). Forty of 144 (30%) hypoxanthine phosphoribosyltransferase (HPRT)-positive and FIAU-resistant clones, screened for homologous recombination by Southern blot analysis using 5'- and 3'-specific probes, were found to have correct targeting events. Injection of mutant ES clones was performed, and successful germ line transmission from two independent cell lines was achieved. Mice from the two independent ES cell lines were bred and maintained separately. There was no difference in the gross phenotype between the two lines, and the results reported here were observed with both lineages.
![]() View larger version (46K): [in a new window] |
FIG. 4. Disruption of Pam14 by gene targeting. (A) Structure of the Pam14 targeting construct. Abbreviations: E5, EcoRV; B1, BamHI; Xb, XbaI; Xh, XhoI; N1, NotI; S1, SmaI. (B) Northern blot of mRNA isolated from brain, liver, lung, spleen, and testis. The lower panel shows 18S and 28S rRNA stained with ethidium bromide as a loading control. (C) Western blot of whole-splenocyte lysates from mutant and control mice, using rabbit anti-PAM14 antibody against full-length hPAM14. (D) Southern blot analysis of tail DNAs from 3-week-old progeny of a Pam14+/ intercross. These results were obtained from two independent litters.
|
PAM14 is not required for normal development and has no effect on the aging phenotype. Heterozygous mice were intercrossed, and F2 offspring were genotyped at 3 weeks of age by Southern blotting; all three genotypes were detected (Fig. 4D). Wild-type, Pam14+/, and Pam14/ offspring from heterozygous crosses were obtained in the expected Mendelian ratio (Table 1). Pam14/ mice developed normally and were not grossly different from wild-type and heterozygous littermates. This indicated that PAM14 is not required for normal development. Both male and female Pam14/ mice were fertile. We have maintained Pam14/ mice for over 2 years and observed no differences with aging compared with control littermates.
|
View this table: [in a new window] |
TABLE 1. Genotype analysis of F2 mice at 3 to 4 weeks of age from heterozygous x heterozygous intercrosses
|
![]() View larger version (23K): [in a new window] |
FIG. 5. IL-2 production by wild-type, Pam14+/, and Pam14/ T cells. Splenocytes from 8-week-old wild-type, heterozygous, and homozygous mutant Pam14 mice were stimulated with various concentrations of ConA for 48 h. The production of IL-2 was determined by ELISA. The results are representative of two independent experiments.
|
![]() View larger version (64K): [in a new window] |
FIG. 6. MEF analyses. (A) Cell proliferation was measured by the 3T3 protocol. At 3-day intervals, the total number of cells per 60-mm culture dish was counted prior to redilution to 3 x 105 cells per dish for the next passage. The results are representative of at least three independently derived lines of MEFs per genotype. (B) Expression patterns of cell cycle-regulated genes by Northern blot analysis. Quiescent MEFs were stimulated by adding 10% FBS-containing medium, and total RNA was isolated at the indicated time points (hours after stimulation). The expression of cyclin E1 (Ccne1), cyclin D1 (Ccnd1), Mybl2, Myc, Mrg15, Pam14, and Gapd mRNAs was detected by Northern blotting.
|
|
|
|---|
PAM14 was previously isolated by our group as an MRG15/MRGX-interacting protein in a yeast two-hybrid screen (13). We have previously shown that PAM14 is present in a complex with MRG15 and Rb in various human cells by sucrose gradient separation, coimmunostaining, and coimmunoprecipitation (20). A large amount of the total MRG15 protein appears to associate with this complex, and we hypothesize that this may form the basic complex found in most cell types and that PAM14 may help to stabilize this complex by acting as an adaptor protein.
Our laboratory has also identified another MRG15-containing complex (MAF2) by sucrose gradient separation (20). The MAF2 complex contains MOF, one of the MYST family histone acetyltransferases (18), and corresponds to the budding yeast NuA4 histone acetyltransferase complex, which has been purified and contains the MRG15 ortholog Eaf3p (6). The MAF2 complex does not include PAM14, and a PAM14 homolog does not exist in yeast. Thus, PAM14 and PAM14-related proteins probably evolved in mammalian systems, which are more complex.
Similarly, Rb, which is another component of the MRG15/PAM14 complex, has no homolog in yeast. However, it is one of the important tumor suppressor proteins that negatively control the cell cycle (4). Rb/ MEFs are not more easily immortalized than wild type because other Rb family members, p130 and p107, compensate for this function (5, 24); however, cyclin E1 expression in the G0 state is maintained at high levels and time to entry into S phase is shortened (8, 11). Cyclin E1 expression in Pam14/ MEFs is not upregulated in G0 phase. Moreover, the mRNA expression pattern of cyclin E1 as well as that of the genes cyclin D1, Mybl2, and Myc, which are known to be regulated by the Rb family proteins and E2F, are the same in Pam14/ and Pam14+/ MEFs as well as in wild-type MEFs. The Rb family proteins are involved in maintaining peripheral T lymphocytes in a quiescent state. Although p130 is primarily responsible for this in resting T lymphocytes, it is known that Rb and p107 can functionally compensate for p130 in these cells (17). Pam14/ splenic T lymphocytes produced IL-2 in response to ConA and PMA plus ionomycin to the same levels as wild-type and Pam14+/ T cells and were not hypo- or hyperresponsive to these stimulants. Finally, Rb+/ mice develop pituitary and thyroid tumors within 1 year (9, 15, 33), but Pam14/ mice appear to be healthy at that time. These data suggest that PAM14 is not required for Rb function or inactivation because there may be redundant molecules or pathways that compensate for it.
A database search using the Pam14 cDNA sequence did not find homologs with high sequence similarity. However, PAM14 is a small protein (14 kDa), and the only known protein motif is a coiled-coil region. Many proteins, including transcription factors, have this motif, which is known to function in mediating protein-protein interactions (3, 10, 14). In budding yeast, it is predicted that 9% (1 in every 11) of proteins contain a coiled-coil sequence (19, 34), and many associations between coiled-coil regions of proteins have been confirmed by the yeast two-hybrid assay (19). Therefore, a functionally redundant molecule(s), with a coiled-coil motif, similar to that of PAM14 must exist in mammalian cells and compensate for PAM14 function(s) in null mice. The result is a lack of a definitive phenotype in null versus wild-type mice.
This work was supported by grants from the NIA, P01AG2752, and the Ellison Medical Foundation (O.M.P.S.) and NCI CA60651 (M.M.M.).
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»